Overview

This trial is active, not recruiting.

Condition type 1 diabetes
Treatments dose d1 of interleukin-2, placebo, dose d2 of interleukin-2, dose d3 of interleukin-2
Phase phase 2
Sponsor Assistance Publique - Hôpitaux de Paris
Start date June 2013
End date December 2016
Trial size 24 participants
Trial identifier NCT01862120, P101106

Summary

Human recombinant interleukin-2 (rhIL-2) is a biological signalling protein playing a key role in the regulation of the immune system. At high doses, rhIL-2 activates the immune effectors T cells (TEFFS) while at low doses rhIL-2 induces and activates regulatory T cells (TREGS), a population of immune cells controlling the immune Teff response. In patients with Type 1 Diabetes (T1D), TREGS fail to control the autoimmune destruction by TEFFS of pancreatic beta-cells producing insulin. The investigator recently showed that rhIL-2 at low dose is well tolerated in patients with an autoimmune disease and in adults with established T1D, inducing TREGS without effects on TEFFS. The investigators aim to use rhIL-2 at low dose to induce/stimulate TREGS in young recently diagnosed T1D patients. This study will investigate the dose effect relationship of low dose rhIL-2 on TREG induction such as to optimize the risk benefit ratio of this treatment in T1D. Through Treg induction, the investigators aim to protect the remaining/regenerating pancreatic β-cells from autoimmune destruction, thus improving or even curing T1D.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking single blind (subject)
Primary purpose treatment
Arm
(Experimental)
Dose D1 of interleukin-2
dose d1 of interleukin-2
subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
(Experimental)
Dose D2 of interleukin-2
dose d2 of interleukin-2
subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
(Experimental)
Dose D3 of interleukin-2
dose d3 of interleukin-2
subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
(Placebo Comparator)
placebo
placebo
subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).

Primary Outcomes

Measure
Treg response following the induction cure period
time frame: day 5

Secondary Outcomes

Measure
Fasting plasma concentration of C-peptide
time frame: at Day 0, 99, 183, 267, 351, 436
C-peptide AUC response to a mixed meal tolerance test
time frame: at baseline, at months 6, 12, 15
IDAA1C score
time frame: at baseline, at months 3, 6, 9, 12, 15
HbA1c
time frame: at baseline, at months 3, 6, 9, 12, 15
Treg response after the last administration
time frame: day 351, day 436
Treg response during the maintenance period compare to the baseline
time frame: day 15, day 29, day 43, day 99, day 183, day 267

Eligibility Criteria

Male or female participants from 7 years up to 14 years old.

Inclusion criteria : - Age [7-13] years for girls and [7-14] years for boys - With a T1D diagnosis (as ADA) - Treated with insulin for ≤ 3 months, - With at least one auto-antibody among: anti-insulin, anti-GAD, anti-IA2, anti-ZnT8 ; - No clinically relevant abnormal findings for haematology, biochemistry, liver and kidney functions - Informed consent signed by the patient, the parents, and the investigator before any intervention necessary for the trial. Exclusion criteria : - Contra-indications to IL-2 : - Hyper sensibility to IL-2 or its excipients, - Severe cardiopathy - Previous organ allograft - Ongoing infection requiring antibiotherapy, - O2 Saturation ≤ 90 % - Severe impairment of any vital organ - Documented history of other auto-immune diseases (except for auto-antibodies for, IAA, GADA, IA-2A, anti-ZnT8A, and stable thyroiditis with normal TSH (<10 mUI/L), T3 and, T4 levels. - Diabetes onset characteristics including: - Continuous nocturnal polyuria ≥ 3 months ; - Inaugural acidosis (with venous Ph < 7.25) ; - HbA1c at diagnostic ≥ 13%; - Weight loss ≥ 10 % at diagnosis ; - Positive autoantibodies to 21-hydroxylase - Stage 2 obesity - Non authorized concomitant treatment : immuno-modulators, cytotoxic drugs, drug modifying plasma glycemia - vaccination ≤ 4 weeks with life vaccin - Positive serology (IgM) to the Epstein-Barr virus (EBV) and/or cytomegalovirus (CMV), reflecting an acute infection. - Participation to another clinical investigation in previous 3 months - No affiliation to National Health Insurance

Additional Information

Official title Induction of Regulatory T Cells for the Treatment of Recently Diagnosed Type 1 Diabetes: Dose Finding Study of the Lowest Active Dose of IL-2 in Children
Principal investigator David Klatzmann, MD, PhD
Description Main objective: Define the lowest dose of rhIL-2 inducing TREGS in children with recently diagnosed type 1 diabetes. Conduct of the study: Three doses will be studied versus placebo in parallel groups of six patients. Each dose or placebo will be studied according to three periods of treatment: 1. Induction of TREGS following a cure of 5 days repeated once daily administration [day 1 - day 5]. 2. Maintenance of TREGS following repeated administration once every two weeks for one year [day 15 - day 337]. At each treatment period, Treg response and tolerance will be evaluated. In addition, overall response on T1D parameters will be assessed throughout the study.
Trial information was received from ClinicalTrials.gov and was last updated in April 2016.
Information provided to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris.